Martin P. Sutter - 02 Jun 2026 Form 4 Insider Report for Bioventus Inc. (BVS)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: BVS
Reported as of: 02 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Jun 2026, 16:48:01 UTC
Prior SEC filing: 04 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Anthony D'Adamio, Attorney-in-Fact

Key filing fact

Martin P. Sutter filed Form 4 for Bioventus Inc. (BVS) on 04 Jun 2026.

Key facts

This page summarizes Martin P. Sutter's Form 4 filing for Bioventus Inc. (BVS).
3 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 04 Jun 2026, 16:48.

Change

Previous filing in this sequence was filed on 04 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001017832 Primary reporting owner

SUTTER MARTIN P

Relationship: Director, 10%+ Owner
Address: 4721 EMPEROR BOULEVARD, SUITE 100, DURHAM
Signature: /s/ Anthony D'Adamio, Attorney-in-Fact
Signature date: 04 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BVS transaction

Class A Common Stock

Options Exercise

Transaction value
Shares: +32,282
Change %: +38%
Price: $0.000000^*
Shares after: 117,523
Date: 02 Jun 2026
Ownership: Direct

BVS holding

Class A Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 13,021,324
Date: 02 Jun 2026
Ownership: See Footnote
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BVS transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -32,282
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Jun 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 32,282
Exercise price
Footnotes: F2, F3

BVS transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +25,146
Change %
Price: $0.000000^*
Shares after: 25,146
Date: 03 Jun 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 25,146
Exercise price
Footnotes: F2, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Includes 12,096,702 shares of Class A Common Stock held by EW Healthcare Partners Acquisition Fund, L.P. ("Essex Stockholder") and 924,622 shares of Class A Common Stock held by White Pine Medical, LLC ("White Pine"). EW Healthcare Partners Acquisition Fund UGP, LLC ("General Partner") is the general partner of EW Healthcare Partners Acquisition Fund GP, L.P., which is the general partner of Essex Stockholder, which is the managing member of White Pine. Messrs. Sutter, Vainio, Eastman, and Barry (collectively, the "Managers") are the managers of the General Partner. The Managers disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein.

Footnote F2

Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.

Footnote F3

The RSUs vested on June 2, 2026.

Footnote F4

The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date.